Jefferies Starts Lexicon Pharmaceuticals (LXRX) at Hold, 'Heart Failure Approval is Likely, But Market Uptake Less Clear'
Tweet Send to a Friend
(Updated - March 7, 2023 5:10 AM EST)
Jefferies analyst Andrew Tsai initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Andrew Tsai initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
